Table 1.
Subjects (N = 25) | Controls (N = 25) | |||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Mean/SD | Range | N (%) | Mean/SD | Range | N (%) | Normal Range | P | |
Age in years | 64.4/7.7 | 49-81 | 23 (100) | 59.6/6.8 | 45-77 | 25 (100) | .67 | |
Ethnic | ||||||||
Caucasian | 17 (68) | 17 (68) | ||||||
African-American | 5 (20) | 5 (20) | ||||||
Others | 3 (12) | 3 (12) | ||||||
Clinical T stage | ||||||||
T1 (a-c) | 6 (24) | 23 (92) | ||||||
T2 (a-c) | 15 (60) | 2 (8) | ||||||
T3 (a-c) | 4 (16) | |||||||
Gleason score (median) | 6.5/1.1 | 7-9 | 3.8/1.1 | 1-4 | .01 | |||
Karnofsky score | 89.6/2 | 80-90 | 95.3/1.3 | 90-100 | .09 | |||
BMI | 30.1/4.2 | 22.9-40.7 | 32.8/3.6 | 24.9-39.7 | ||||
Depression | ||||||||
Baseline | 1.2/2.1 | 0-8 | 0.5/0.6 | 0-2 | .11 | |||
Midpoint | 2.9/3.9 | 0-13 | ||||||
Completion | 1.8/2.2 | 0-8 | ||||||
PSA Levels (ng/mL) | 0.0-4.0 | |||||||
Baseline | 21.2/27.4 | 0.61-111 | ||||||
Completion | 0.46/0.98 | 0.01-4.84 | ||||||
Hematocrit (%) | 40.1-51.0 | |||||||
Baseline | 40.3/3.8 | 32.9-46.9 | ||||||
Completion | 36.8/2.9 | 33.0-42.0 | ||||||
Albumin Levels (g/dL) | 3.7-4.7 | |||||||
Baseline | 3.9/0.3 | 3.5-4.5 | ||||||
Testosterone (ng/dL) | 181-758 | |||||||
Baseline | 245.7/168.1 | 20-537 | ||||||
TSH (μIU/mL) | 0.4-4.0 | |||||||
Baseline | 1.8/1.2 | 0.17-3.8 | ||||||
Total dosage of EBRT (Gray) | ||||||||
75.6 | 23 (92) | |||||||
68.4 | 2 (8) |
ng/dL = nanogram per deciliter; μIU/mL = micro International Units per milliliter; ng/mL = nanogram per milliliter; BMI= body mass index, PSA= prostate specific antigen, ng= nanogram, ml= milliliter, g= gram, dl= deciliter, TSH= thyroid stimulating hormone, mcl= microliter, EBRT= external beam radiation therapy